Genentech’s Evrysdi Continues to Improve Motor Function and Survival in Babies With Type 1 Spinal Muscular Atrophy (SMA)

– More than twice as many babies (61% vs. 29%) were able to sit without support for at least five seconds after 24 months compared to 12 months of treatment – – Evrysdi increased survival and reduced need for permanent ventilation – – Evrysdi has proven efficacy across adults, children and babies 2 months and … [Read more…]

agilon health Announces Pricing of Initial Public Offering

LONG BEACH, Calif.–(BUSINESS WIRE)–agilon health, inc. (“agilon health”), which partners with primary care physicians to unlock value-based healthcare delivery, announced the pricing of its initial public offering of 46,600,000 shares of its common stock at a public offering price of $23.00. All of the shares of common stock are being offered by agilon health. The … [Read more…]

Nexus Pharmaceuticals Makes Key Investment to Help COVID-19 Vaccine Effort

PLEASANT PRAIRIE, Wis.–(BUSINESS WIRE)–#AmericanMade–Nexus Pharmaceuticals Inc., a US-based healthcare company and domestic manufacturer, today announced that they transported via a special air freight charter through DB Schenker 82 tons of vaccine filling equipment, including a vaccine filling machine and isolator from Bausch + Stroebel and Franz Ziel. Once the production line is operational, Nexus will … [Read more…]

CLSI Publishes M100—Performance Standards for Antimicrobial Susceptibility Testing, 31st Edition

MALVERN, Pa.–(BUSINESS WIRE)–The Clinical and Laboratory Standards Institute (CLSI) has published M100—Performance Standards for Antimicrobial Susceptibility Testing, 31st Edition. The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in M02, M07, and M11. Users should replace previously published tables with these new tables. … [Read more…]

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cabometyx® (cabozantinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Approval based on Phase 3 CheckMate -9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall survival and doubled median progression-free survival and objective response rates compared to sunitinib Opdivo in combination with Cabometyx was generally well tolerated, with a low rate of treatment-related discontinuations Two Opdivo-based therapies are now authorized for first-line … [Read more…]

AXIS Capital Provides Initial Comments on First Quarter Results

PEMBROKE, Bermuda–(BUSINESS WIRE)–$AXS #earnings–AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced a preliminary first quarter net loss estimate for catastrophes and other weather-related events in the range of $105 million to $115 million, pre-tax ($95 million to $105 million, after-tax). The pre-tax net loss estimate includes an amount of $80 … [Read more…]

Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5

Conference Call and Webcast Scheduled for 1:30 p.m. PDT SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The … [Read more…]

AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

VANCOUVER, British Columbia & SAN DIEGO–(BUSINESS WIRE)–$ABCL—AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strategic multi-target discovery collaboration. Through each company’s proprietary technologies, the multi-target collaboration leverages hyper-scale datasets, machine learning, and advanced computation to both identify high-value, genetically-validated drug targets and discover novel therapeutic antibodies. Empirico will … [Read more…]

Cross Country Healthcare Announces First Quarter 2021 Earnings Release Date and Conference Call Information

BOCA RATON, Fla.–(BUSINESS WIRE)–Cross Country Healthcare, Inc. (Nasdaq: CCRN) will hold its quarterly conference call to discuss its first quarter 2021 financial results on Wednesday, May 5, 2021 at 5:00 p.m. Eastern Time. Cross Country Healthcare, Inc. (the “Company”) intends to distribute its earnings press release after market close on Wednesday, May 5, 2021. This … [Read more…]

Masimo to Report First Quarter 2021 Financial Results after Market Close on Tuesday, April 27

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) IRVINE, Calif.–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) will release first quarter 2021 financial results for the period ended April 3, 2021, after the market closes on Tuesday, April 27, 2021. The conference call to review the results will begin at 1:30 p.m. PT (4:30 … [Read more…]